Physician profile
Eva Leinart
NPI 1003199282
$8,136.23
in general payments reported to CMS, 2019-2025
45 companies · $3,774 in 2025
The $3,774 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $335 · 2021: $846 · 2022: $780 · 2023: $727 · 2024: $1,199 · 2025: $3,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,200 · Food and Beverage: $2,461 · Education: $40.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,200.00 |
| Food and Beverage | $2,460.59 |
| Education | $40.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $3,200.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $902.17 | 2019-2025 | |
| Sage Therapeutics, LLC | $312.75 | 2024-2025 | Zurzuvae |
| Organon LLC | $309.14 | 2021-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $283.72 | 2021-2025 | |
| Hologic Sales and Service, LLC | $211.61 | 2021-2025 | Aptima |
| Aspira Women'S Health INC | $209.26 | 2021-2023 | Ova1 |
| Coopersurgical, INC. | $197.03 | 2019-2025 | Endosee, Paragard T 380a, Sos |
| Millicent US INC | $188.69 | 2023-2025 | Intrarosa, Femlyv, Femring |
| Bayer Healthcare Pharmaceuticals INC. | $185.25 | 2019-2025 | |
| Therapeuticsmd, INC. | $161.64 | 2019-2022 | |
| Astellas Pharma US INC | $159.84 | 2024-2025 | Veozah |
| Medtronic, INC. | $151.59 | 2021-2025 | V-Loc 180, Ligasure |
| Channel Medsystems, INC. | $151.41 | 2022-2023 | |
| Novo Nordisk INC | $144.21 | 2023-2025 | Saxenda, Wegovy |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $141.44 | 2023-2025 | Accrufer |
| Merck Sharp & Dohme LLC | $137.90 | 2019-2023 | Gardasil 9 |
| Daiichi Sankyo INC. | $92.84 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $89.63 | 2025 | Myfembree |
| Pacira Pharmaceuticals Incorporated | $82.30 | 2023-2025 | Exparel |
| Amgen INC. | $79.59 | 2019-2025 | Evenity |
| Agile Therapeutics, INC. | $73.34 | 2021-2022 | |
| Smith+Nephew, INC. | $59.47 | 2019-2025 | Pico 14, Pico |
| Exeltis, USA INC. | $59.21 | 2020-2025 | Slynd |
| Avanos Medical | $49.35 | 2019 | |
| Supernus Pharmaceuticals, INC. | $46.49 | 2025 | Qelbree |
| Lilly USA, LLC | $45.85 | 2024-2025 | Zepbound, Mounjaro |
| Evofem Biosciences, INC. | $39.56 | 2021 | |
| Mylan Pharmaceuticals INC. | $37.76 | 2019-2020 | |
| Pfizer INC. | $32.01 | 2019-2020 | |
| Radius Health, INC. | $28.97 | 2019-2020 | |
| Sanofi Pasteur INC. | $26.21 | 2025 | |
| Baxter Healthcare | $24.19 | 2023 | Seprafilm |
| Lupin INC. | $23.82 | 2019-2020 | |
| Exact Sciences Corporation | $21.78 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $21.65 | 2019 | |
| Genzyme Corporation | $21.52 | 2025 | |
| Minerva Surgical, INC | $20.93 | 2025 | |
| Pharmacosmos Therapeutics INC. | $20.17 | 2021 | |
| Acell, INC. | $20.13 | 2019 | |
| Avion Pharmaceuticals | $19.46 | 2020 | |
| Olympus America INC. | $14.41 | 2019 | |
| Scynexis, INC. | $13.98 | 2022 | |
| Duchesnay USA Incorporated | $12.59 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Leinart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.